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ChelationTransfusion and iron chelation treatment have signiﬁcantly reduced morbidity and improved survival of pa-
tients with thalassemia major. However, cardiac disease continues to be the most common cause of death.
We report the left-ventricular ejection fraction, determined by echocardiography, in one hundred sixty-eight
patients with thalassemia major followed for at least 5 years who received continuous monotherapy with
deferoxamine (N = 108) or deferiprone (N = 60). The statistical analysis, using the generalized estimating
equations model, indicated that the group treated with deferiprone had a signiﬁcantly better left-ventricular
ejection fraction than did those treated with deferoxamine (coefﬁcient 0.97; 95% CI 0.37; 1.6, p = 0.002).
The heart may be particularly sensitive to iron-induced mitochondrial damage because of the large number of
mitochondria and its low level of antioxidants. Deferiprone, because of its lower molecular weight, might cross
into heart mitochondria more efﬁciently, improving their activity and, thereby, myocardial cell function.
Our ﬁndings indicate that the long-term administration of deferiprone signiﬁcantly enhances left-ventricular
function over time in comparison with deferoxamine treatment. However, because of limitations related to
the design of this study, these ﬁndings should be conﬁrmed in a prospective, randomized clinical trial.
© 2013 Elsevier Inc. All rights reserved.Introduction
Thalassemia is one of the most common genetic diseases worldwide
with at least 60,000 severely affected subjects being born every year [1].
Iron overload is amajor concern in these patients because of the need for
red cell transfusions. Transfusion and iron chelation treatment have
signiﬁcantly improved survival and reduced morbidity in thalassemia
major during the last three decades [2,3].
The effectiveness of chelation therapy has improved as a result of the




g-term treatment with defer
ajor, Blood Cells Mol. Diseas(DFX). Each chelator canbe given asmonotherapy.DFP anddeferoxamine
(DFO) have been widely used in combination.
The detection and management of cardiac damage have improved
over the last 10 years because of cardiac magnetic resonance-T2*
(CMR-T2*) imaging, a non-invasive tool with which to monitor car-
diac function associated with iron body burden [4,5]. Cardiac disease
continues to be the most common cause of death in patients with
thalassemia major [3,6,7]. Chelation therapy is aimed at improving
myocardial function, as judged by the left ventricular ejection fraction
(LVEF).
A multicenter, randomized, open-label, long-term, study of sequen-
tial DFP–DFO compared to DFP has been reported in patients with thal-
assemia major to assess LVEF [8]. Improvement in the LVEF after 1-year
of DFP treatment versus DFO was even found [9,10]. However, the effectiprone enhances left ventricular ejection function when compared to
es (2013), http://dx.doi.org/10.1016/j.bcmd.2013.04.002
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reported to our knowledge.
The aim of this study was to show if there was any difference in
myocardial function as determined by 2-D echocardiography LVEF
assessmentwhenDFP andDFO treatment of thalassemiamajor patients
was compared over a longer time period.
Materials and methods
Patients and treatment
This was a retrospective study of 168 patients with thalassemia
major. Baseline clinical ﬁndings are shown in Table 1. All patients re-
ceived at least 4 years of continuousmonotherapywith DFO or DFP che-
lation treatment between September 30, 2002 and September 30, 2008.
All enrolled subjects had echocardiographic study for LVEF. Among
these, 108 received DFO treatment whereas 60 received DFP treatment
(Table 1). DFO (Biofutura Pharma, Pomezia, Italy) was administered at
50 mg/kg per day by subcutaneous infusion (8–12 h) for 7 days. DFP
(Apotex, Toronto, ON, Canada) was administered at 75 mg/kg, divided
into three oral daily doses, for 7 days a week. Chelation treatment was
stopped or dose was adjusted in case of occurrence of severe adverse
events (SAEs). Compliance was assessed by counting the pills in each
returnedbag of DFP and by assessing the number of infusions of DFO reg-
istered on the electronic pump (CronoTM, Gene S.r.l., Italy).
Methods
LVEF was deﬁned as the fraction of end-diastolic volume that is
ejected by the left ventricle in each beat. It was measured by a single
operator with two-dimensional (2-D) echocardiography assessments
dividing the stroke volume by the end-diastolic volume in each patient
(Vivid S5, Gems Ultrasound, Tirat Carmel, Israel). Two-dimensional echo-
cardiography was used to determine the LVEF and volumes (single plane
area-length method), and to calculate right ventricular end-diastolic and
end-systolic areas by planometry from the four-chamber view, according
to previous recommendations [11]. The diagnosis of heart disease was
based on standard clinical and instrumental ﬁndings including echocar-
diography and electrocardiogram [12]. Liver iron content (LIC) was de-
termined on liver biopsies with an atomic spectrophotometer. Liver
biopsy was performed only in patients on interferon treatment for
chronic C hepatitis [13].
Statistical models
The generalized estimating equations (GEE) model was used [14] to
evaluate if there was a statistically signiﬁcant variation of LVEF overTable 1
Baseline ﬁndings in the 168 patients included in this retrospective cohort study.
Findings DFO-group DFP-group p-Value
No. pts (168) 108 60
Females no. (%) 55(51) 22 (37) 0.25
Age in years 32 ± 8.0 31 ± 7.0 0.26
Hemoglobin, g/L* 9 ± 0.83 9 ± 0.87 0.91
ALT, IU/L* 53 ± 39 50 ± 38 0.71
LIC, g/g per dw 3.3 ± 3.8 2.9 ± 2 0.61
Total transfusion, L/kg per year 9 ± 3 8.7 ± 2.1 0.51
Mean ferritin, mg/L 1.5 ± 1.1 1.7 ± 0.84 0.37
Mean basal EF b55% (no.) 45 ± 8.0 (26) 52 ± 2.0 (6) 0.05
Basal mean ejection fraction 58 ± 10 59 ± 4 0.23
Mean age at DFO starting, years 6 ± 6 6 ± 4 0.99
Splenectomy no. (%) 59 (60) 26 (44) 0.18
Cirrhosis no. (%) 21 (20) 5 (8.0) 0.01
Arrhythmia no. (%) 16 (15) 11(18) 0.81
HCV-RNA positive no. (%) 40 (42) 18 (30) 0.38
ALT, alanine aminotransferase; dw, dry weight; EF, ejection fraction; HCV, hepatitis C
virus; IU, international units; LIC, liver iron content.
Please cite this article as: A. Filosa, et al., Long-term treatment with defer
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and if this variation in the LVEF was statistically different between the
two treated groups. LVEF values consisted of repeated observations
over time on the same patient. These measurements, taken on the
same patient, may not be independent one from another. One appro-
priate model, taking into account for the issue that repeated measure-
ments might be correlated, is the generalized estimating equations
(GEE)model [14]. This model includes the treatment-effect (treatment),
the time-effect (time) and the treatment-by-time interaction effect
(treatment × time) of the considered variables. This approach was
implemented using the “xtgee” procedure in the Stata 11 software
(Stata Corporation, College Station, TX, USA). These ﬁndings are
reported on Table 2 and Fig. 1.Moreover, yearly LVEF%, in both chelation
groups divided by b55 and >55, was reported in Table 3. Patient base-
line clinical ﬁndings were reported withmeans and standard deviations
(SD) for continuous variables and as proportions for dichotomous
variables. All of the statistical analyses were performed under code at
the Dipartimento di Scienze Economiche, Aziendali e Statistiche, Univer-
sity of Palermo (Italy).Results
All patients were over 13 years of age (Table 1). The prevalence of
males was higher in the DFP treatment group (Table 1). Among the
168 patients, 108 received DFO and 60 received DFP chelation treatment
(Table 1). Baseline hematological, cardiac, and body iron burden ﬁnd-
ings, evaluated as serum ferritin level, LIC, total number of blood transfu-
sions, arrhythmia, HCV-RNA positivity, and mean age at the start of
chelation treatment were not signiﬁcantly different between the two
treated groups (Table 1). Presence of cirrhosis showed a statistically sig-
niﬁcant difference, at baseline, between DFP versus DFO group (Table 1).
Compliance was 92 ± 7% (range 37–100%) and 70 ± 6% (range
25–100%) in the DFP versus the DFO treatment groups, respectively.
The serum ferritin levels at the end of the study were 1.4 ± 0.96 versus
1.6 ± 0.91 mg/L (p b 0.01) in DFO compared to DFP, respectively. The
pre-transfusional Ηb level was not statistically different between the
two chelation groups (t = 1.6, p = 0.12), excluding this ﬁnding as a
possible bias of the study.
The statistical analysis, evaluated by GEE model, indicated that the
DFP treated group had a signiﬁcant increase over time of mean LVEF
in comparison with the DFO treated group (Coefﬁcient 0.97, 95% CI
0.37; 1.6, p = 0.002, Table 2 and Fig. 1). No statistically signiﬁcant
variation was found for the DFO-group over time (coefﬁcient −0.43,
95% CI (−1.2; 0.32), p = 0.26, Table 2 and Fig. 1).
The coefﬁcient of the treatment-effect, indicating the difference
between treatments, showed that therewas not a statistically signiﬁcant
difference of LVEF between the two treated groups (coefﬁcient −0.96,
95% CI−3.6; 1.7), p = 0.47, Table 2 and Fig. 1). Table 3 showed that in
the patients with a LVEF less than 55%, half (3 of 6) of DFP-treated
group had an improved LVEF at the end of the study. Indeed, noTable 2
GEE model to evaluate changes in mean ejection fraction levels in deferiprone (DFP)-group
versus deferoximine (DFO)-group over time.
Coefﬁcients (SE*) 95% CIa p-Valueb
Intercept 58 (1) (56–60) b0.0001
Treatmentc −0.96 (1) (−4.0; 2.0) 0.47
Timec 0.97 (0,31) (0.37; 1.6) b0.01
Treatment × Timed −0.43 (0,38) (−1.0; 32) 0.26
a SE = standard error, CI = conﬁdence interval.
b p-Value from null hypothesis coefﬁcient = 0 by Wald's test.
c Treatment is the variable indicating if a patient belongs to DFP-group or DFO-group;
time is the variable indicating the consecutive years of observation, corresponding to
t = 1, 2, 3, 4.
d Treatment × Time is the interaction effect between Treatment and Time.

















Fig. 1. Estimated proﬁles from the ﬁtted generalized estimating equations (GEE) model
for the deferiprone (DFP)-group and deferoxamine (DFO)-group. The baseline left ven-
tricular ejection fraction (LVEF) for DFO group is 58 ± 10% and for the DFP group is
59 ± 4%.
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greater than 55% group (Table 3).
Discussion
The improvement of the LVEF after 1-year of DFP treatment as
compared to DFO treatment has been described [9,10]. However, no
comparison of LVEF in patients treated long-term with DFP compared
to DFO has been reported.
Three retrospective studies and one-year prospective randomized
trial have conﬁrmed the superiority of DFP compared with DFO at re-
moving cardiac iron as assessed by T2* MRI [15–18].
Moreover, different retrospective studies, in patients with thalasse-
miamajor, found that DFPwas superior in comparison to DFO treatment
in preventing cardiac death [19–21]. Whereas no cardiac deaths and no
new cardiac events occurred in the DFP treated group, 10 cardiac deaths
and 42 non-fatal cardiac events occurred in the DFO treated group [19].
This effect was not related to the serum ferritin levels [19]. The greater
improvement of LVEF over time, obtained in the long-term DFP-treated
group reported in this paper, may explain the results obtained in these
previous clinical studies.
Moreover, similar ﬁndings have been described assessing retro-
spectively the variation of LVEF during the multicenter randomized,
open-label, long-term, sequential DFP–DFO treatment compared to
DFP-alone [8]. In this study, 99 patients underwent long-term echo-
cardiography evaluation of LVEF, measured at baseline and everyTable 3




0 1 2 3
DFO no. (%) 26 (24) 17 (16) 22 (20) 20 (18)
DFP no. (%) 6.0 (10) 4.0 (7.0) 5.0 (8.0) 3.0 (5.0)
LVEF >55%
Years
0 1 2 3
DFO no. (%) 82 (76) 91 (84) 86 (80) 88 (81)
DFP no. (%) 54 (90) 56 (93) 55 (92) 57 (95)
DFO, deferoximine; DFP, deferiprone; LVEF, left ventricular ejection fraction.
Please cite this article as: A. Filosa, et al., Long-term treatment with defer
deferoxamine in patients with thalassemia major, Blood Cells Mol. Diseas12 months over three consecutive years. Among these, 39 and 60 re-
ceived sequential DFP (75 mg/kg for 4 days/week)–DFO (50 mg/kg for
3 days/week) treatment or DFP treatment (75 mg/kg for 7 days/week).
The paper concluded that DFP treatmentwas able to enhance LVEF, as de-
termined by echocardiography, over time in comparison with sequential
DFP–DFO [8].
A small increase in LVEF during one-year of chelation treatment
among thalassemia major patients might be expected to reduce the
risk of heart failure [22]. Changes in LVEF (3.1% vs. 2.6%), measured
by CMR-T2*, during DFP or combined DFP–DFO treatment were asso-
ciated with a risk reduction for the development of heart failure over
12 months (46% vs. 26%, respectively) [22]. Therefore, relatively small
changes in LVEF may assume clinical importance for patients with
thalassemia major.
A decrease in mean LVEF ≥7%, as determined by 2-D echocardiog-
raphy, was a strong predictive tool for identifying thalassemia pa-
tients at risk for death from heart failure in a cohort of 188 patients
with thalassemia major who had serial observations of LVEF mea-
surements for at least four consecutive years [23]. The paper reported
the risk of death due to cardiac failure in patientswith amean reduction
of LVEF >7%, was 4.93 with a 95% conﬁdence interval of 1.6 to 15.0
(p = 0.005) [23]. The median time from the last echocardiography to
death was 3 years. The ROC curve to detect a decrease in LVEF ≥7%
showed high sensitivity (85%) in predicting increased risk of death
[23]. Kaplan–Meier survival curves, in thalassemia major patients with
decreasing LVEF >7%, was associated with a signiﬁcant reduction in
the probability of survival (p = 0.0022) [23].
Iron-mediated damage to the heart, as reﬂected in LVEF function,
may occur in heart cell mitochondria [24]. The heart may be particu-
larly sensitive to iron-inducedmitochondrial damage relative to other
tissues because of the large number of mitochondria that are required
for its high oxygen utilization and its low level of antioxidants [25].
Mitochondria generate ATP as a result of the action of respiratory chain
complexes [26]. Since heart contractility could be down-regulated in
response to the reduced ATP production due to iron-mediated mito-
chondrial damage, the high metabolic demands for increased cardiac
muscle contractionwould depend on the ability to restoremitochondrial
activities and thereby improve myocardial cell function [22].
DFP, because of its lowermolecularweight,may cross cellmembranes
more effectively and chelate iron from intracellular compartments.
Therefore, the drug could protect heart mitochondria and therebymyo-
cardial cell function [27]. A cardio-protective effect of DFP onmitochon-
drial function in cultured, iron-loaded heart cells has been reported,
even at concentrations below the iron-mobilizing effect [28].
However, although these are the most likely hypothesis, the exact
mechanisms remain to be so far fully elucidated.
In conclusion, this retrospective survey indicates that the long-term
administration of DFP signiﬁcantly enhances LVEF over time in compar-
ison with DFO.
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